Tag Archives: panel

RESI Panel Announcement: Biotech Angels Panel

12 Nov

By Christine A. Wu, Research Analyst, LSN

chrsitine

Angel investors have been one of the first go-to investors as an incredibly important source of capital for fundraising entrepreneurs. They provide early stage companies not only with capital, but also with experience and professional knowledge due to their unique membership composition and investment focus.

Furthermore, there is a continuing trend of angels syndicating to participate in larger investment deals with angel investor rounds growing from $800K in 2014 to over $1M to date in 2015.

LSN has assembled accredited Angel investors particularly interested in biotech therapeutics for RESI San Francisco, occurring on January 12th. The Biotech Angels Panel will be moderated by Karl Handlesman, Founder of Codon Capital, and will be joined by:

The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the trends in angel investment in the bio-pharmaceutical field; the perspective of an angel when approaching a deal in the space; and the best approach to initiate dialogue with an angel investor. Angels will explain their investment preferences and their evaluation criteria, and provide overall advice in how to approach and build relationships with them. This will undoubtedly be a tremendous opportunity for biotech life science entrepreneurs to meet angel investors in person.

RESI-San-Francisco-2016

Tags: , , , , , ,

RESI Panel Announcement: Medical Device Investors

12 Nov

By Lucy Parkinson, Senior Research Manager, LSN

Medical technology represents a major segment of life science investment, with $2.7 billion in venture allocations going into devices and diagnostics in 2014.  At LSN, we track over 700 investors who have an interest in development or clinical-stage medical devices.  For RESI San Francisco, LSN has gathered a panel of experienced medical device investors to share their expertise and advice with medtech entrepreneurs.

Moderated by David Cassak, Managing Partner, Innovation In Medtech, our panelists are:

The panel will explore the challenges of raising a financing round in the medical device sector, providing advice for entrepreneurs from early development stages through to commercialization.  These investors will explain what makes a device startup stand out, and how they assess the potential risks of a device opportunity.  If you’d like to join us at RESI, register now.

RESI-San-Francisco-2016

 

Tags: , , , ,

Family Offices Investing in Early Stage Therapeutics: RESI Panel Announcement

20 Nov

By Tom Crosby, RESI Conference Manager, LSN

Tom 2RESI has always aimed to bring a diverse pool of investors together to meet life science entrepreneurs, and at past events, our Family Office panels have often stolen the show.  As family offices grow in importance as a source of critical development capital for life science companies, LSN is excited to announce a second panel drawn from this category of investors: Family Offices Investing in Early Stage Therapeutics.

Family offices represent individuals and families with over $100 million in total assets, and therefore invest amounts far beyond angel capital.  As investors seeking both capital preservation and a long-term impact, many family offices have been taken an interest in biotechnology, a sector where far horizons are required and an investment has the power to make a difference for thousands, even millions, of people suffering from a serious disease.  Moderated by John Nelson, Managing Director of Genrich, Inc. the panel includes the following speakers:

Amir Heshmatpour, Founder & Managing Director, AFH Holding & Advisory

Rick Jones, Director, Broadview Ventures

Melissa Krauth, Head, Life Science Investments, Claria Bioscience

Sean Stalfort, Partner, PBM Capital

What are their particular motivations for investing in therapeutic development?  How does the more flexible nature of a family office structure affect their approach to biotech opportunities?  What, in addition to capital, can these groups bring to the table for an early stage company? How does an entrepreneur find a family office that might be interested in biotech and get in touch, and what information do they look for in the initial correspondence?

bb2

 

Tags: , , ,

Investing in the Future: RESI Conference Announces Corporate VC Panel

3 Jul

By Tom Crosby, RESI Conference Manager, LSN

Tom 2

Corporate Venture Capital (CVC) and Independent Venture Capital are two totally separate beasts with different tactics and strategies – especially regarding early stage investments. Learn from the experts in Corporate Venture Capital why there is a growing interest in early stage life science. As CVC funds continue to grow, it is increasingly important for entrepreneurs to understand these entities as a viable source of potential investment.

The RESI Conference session will feature representatives from some major players in the industry. This is a must attend, one-of-a-kind panel that will provide tremendous insight for the scientist entrepreneur.

Moderated by Vikas Goyal of SR One, the audience will hear from:

Panelists will answer the question regarding independent VCs being friend or foe, and how they are different than independent venture capital. The session will also focus on the individual investment preferences of each representative on the panel. What does their portfolio look like today? What is the best way for early stage entrepreneurs to get on their radar screens?

Tags: , , ,

Newer Entries →